Caricamento...
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lun...
Salvato in:
| Pubblicato in: | Ann Oncol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6267867/ https://ncbi.nlm.nih.gov/pubmed/26371282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv383 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|